Teva enters deal with Sinclair IS for episil commercialisation
This article was originally published in Scrip
Executive Summary
Teva has signed a licence agreement with Sinclair IS Pharma for commercialisation rights to the latter's oncology supportive care product episil in Germany, Spain, Poland, Switzerland and the Czech Republic.